XBiotech (XBIT) EBT Margin (2020 - 2022)

XBiotech (XBIT) posted quarterly EBT Margin of 875.0% for Q4 2022, down 43.32% quarter-over-quarter from 610.54% in Q3 2022.

XBiotech (XBIT) EBT Margin (2020 - 2022) Analysis & Trends

XBiotech's EBT Margin history runs 3 years deep, the most recent figure standing at 875.0% for Q4 2022.

In Q4 2022, EBT Margin changed N/A year-over-year to 875.0%; the TTM figure through Sep 2023 stood at 7401.67% (down 693222.0% YoY), while the FY2022 annual figure was 837.61%, down 69920.0% from the prior year.
EBT Margin for Q4 2022 stood at 875.0%, down from 610.54% in the prior quarter.
The five-year high for EBT Margin was 6.11% in Q4 2020, with the low at 1290.8% in Q1 2022.
The 3-year median for EBT Margin is 111.86% (2021), against an average of 379.09%.
The sharpest annual moves came in 2021 and 2022: EBT Margin tumbled 5990 bps in 2021, then plunged 122802 bps in 2022.
XBiotech's EBT Margin stood at 6.11% in 2020, then slumped by 1930 bps to 111.86% in 2021, then plunged by 682 bps to 875.0% in 2022.
Business Quant data shows XBIT's EBT Margin at 875.0% in Q4 2022, 610.54% in Q3 2022, and 931.5% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	35.61%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	35.71%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-25.06%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	12.09%
10	XBiotech	69.51 Mn	69.51 Mn	-	-

Download Data